Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fiboflapon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP known ✓ | P20292 | 20/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.87 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.87 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fiboflapon SCHEMBL29526863 | 1.00 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1394726 | 0.99 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1254870 | 0.99 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL29617637 | 0.95 | ALOX5AP (0.78) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL19924847 | 0.95 | ALOX5AP (0.78) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL11820 | 0.93 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL12526775 | 0.93 | ALOX5AP (0.90) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29379276 | 0.93 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29723363 | 0.93 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL1394760 | 0.93 | ALOX5AP (0.88) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772495-B2 | 5-lipoxygenase-activating protein inhibitor | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | claimed |
| US-20110160249-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | claimed |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | AMIRA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | claimed |
| US-20260069585-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | Dermavant Sciences GmbH (CH) | 2026-03-12 | — | — | US | disclosed |
| US-20260069553-A1 | TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASES | Dermavant Sciences GmbH (CH) | 2026-03-12 | — | — | US | disclosed |
| US-20250282730-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2025-09-11 | — | — | US | disclosed |
| US-12252471-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| US-20240307374-A1 | FORMULATION OF FURIN INHIBITOR FOR INHALATION | BP ASSET V. INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-17 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20120220779-A1 | Novel Processes | GLAXO GROUP LIMITED (GB) | 2012-08-30 | — | — | US | disclosed |
| US-20120220779-A1 | Novel Processes | GLAXO GROUP LIMITED (GB) | 2012-08-30 | — | — | US | disclosed |
| WO-2011054783-A3 | PROCESSES FOR THE PREPARATION OF 5 - LIPOOXYGENASE ACTIVATING PROTEIN INHIBITORS AND THEIR INTERMEDIATES | GLAXO GROUP LIMITED (GB) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160249-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| WO-2011054783-A2 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054783-A2 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| EP-2285803-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | Amira Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010068311-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | AMIRA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | ALOX5AP 2938/4885PTGS1 1431/4885ALOX5 2169/4885 |
| US-20110160249-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | ALOX5, PRMT5, ALOX5AP | ALOX5AP 3/4885PTGS1 48/4885ALOX5 1/4885 |
| US-12252471-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | ALOX5AP 1217/4885PTGS1 425/4885ALOX5 766/4885 |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | ALOX5AP 1380/4885PTGS1 295/4885ALOX5 420/4885 |
| US-20120220779-A1 | Novel Processes | ALOX5, PNPO, ALOX5AP | ALOX5AP 3/4885PTGS1 126/4885ALOX5 1/4885 |
| US-20250282730-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | ALOX5AP 1217/4885PTGS1 425/4885ALOX5 766/4885 |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | ALOX5AP 1380/4885PTGS1 295/4885ALOX5 420/4885 |
| US-20260069553-A1 | TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASES | AHR, HRH2, HRH4 | ALOX5AP 1104/4885PTGS1 710/4885ALOX5 816/4885 |
| US-20260069585-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | HRH2, AHR, HRH1 | ALOX5AP 1726/4885PTGS1 671/4885ALOX5 1397/4885 |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | ALOX5, LTA4H, ALOX5AP | ALOX5AP 3/4885PTGS1 35/4885ALOX5 1/4885 |
| US-20240307374-A1 | FORMULATION OF FURIN INHIBITOR FOR INHALATION | FURIN, TGFB1, PREP | ALOX5AP 3365/4885PTGS1 1652/4885ALOX5 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.